Grimsby Site Plan Approval, Algoma and BasgenBIO MOU, and New US Provisional with IPON Support

Grimsby Site Plan Approval

We are pleased to share that Canurta has received Conditional Approval for our Facility Site Plan in Grimsby, Ontario. This achievement represents a significant advancement in our efforts to establish a cutting-edge research facility.

Memorandums of Understanding

Algoma University MOU

Canurta Therapeutics is excited to announce a Memorandum of Understanding with Algoma University. This collaborative partnership focuses on advancing research and academic programming in mental health, addictions, and botanical medicine, uniting our expertise and resources with Algoma University's vision to create the Mental Health and Addictions Research and Training Institute in Brampton.

Our joint efforts will focus on promoting scientific research, academic excellence, and community engagement initiatives across key disciplines, including Biology, Psychology, Social Work, Computer Science, and Business Administration. A cornerstone of our partnership is the commitment to fostering knowledge sharing and technology transfer, all while upholding the principles of data sovereignty and community engagement, particularly with Indigenous communities.

BasgenBIO MOU

Additionally, Canurta has signed a Memorandum of Understanding (MOU) with BasgenBIO to evaluate CNR-401 and other assets utilizing their clinops platform. This strategic partnership presents an exciting opportunity to leverage synergies between Canurta and BasgenBIO, based in South Korea. We look forward to exploring collaborative initiatives that will advance our botanical innovation efforts.

New US Provisional with IPON Support

Canurta has filed a US Provisional patent for "Computational Framework for Drug Discovery of Bioactive Therapeutics." This patent pertains to methods and systems for generating novel molecules and optimizing them. We are grateful for the support from Intellectual Property Ontario (IPON), which has played a crucial role in enabling this achievement.

Bringing Canurta's total number of company patents to 22.

F6S Community Rankings for Top Start ups in Canada

Canurta has been recognized as a top innovator in multiple categories for 2024 by F6S, a leading global founder and startup network. Ranked 10th among Health & Wellness companies, 5th among Small Molecules & Peptides companies, and 86th among Food companies in Canada, we're proud to be at the forefront of solving global challenges.

Canurta Speaking Engagements

Canurta Therapeutics will be participating in the Cannabis Innovation Lab’s Pitch and Startup Alley showcase, scheduled for April 16 and April 17, 2024. Our participation in this showcase allows us to present our cutting-edge research and products to a diverse audience of industry leaders, potential investors, and fellow innovators.

Our pitch will focus on our insights into the development of anti-inflammatory and neuroprotective standardized botanical pharmaceuticals, along with our achievements and strategic direction, while the showcase allows us to highlight the unique benefits and functionalities of our multi-target botanical drugs.

As a returning participant, our CEO, Akeem Gardner, will take the stage to share insights from our latest research in a presentation titled "Effect of Cannflavins on Mitigating Motor Neuron Disease,” on May 14, 2024, at 12:15 pm. This presentation will delve into the therapeutic promise of phytochemicals from cannabis in neurodegenerative conditions.

Canurta's March Milestones

Research & Development

New Plant Extract Formulation Update: Our R&D team commenced formulation work on our new plant extract, focused on improving bioavailability. They have also initiated zebrafish studies to determine the efficacy of this extract against anxiety.

Digital Transformation

FilingFlow Update: Phase 2 of FilingFlow, our advanced AI tool tailored to automate compliance tasks and expedite regulatory filings, is nearing completion and deployment.

Bioinformatics

ALS Gene Expression Analysis: This past month, our Bioinformatics team achieved significant milestones in our ALS research, with the Differential Expression Analysis of the Answer ALS dataset. This foundational work led to the exploration of neurodegenerative and neuroinflammatory biomarkers and pathways in ALS, advancing our understanding of this progressive neurological disorder.

These efforts were synthesized into a concise report in the form of a scientific poster presentation that highlights our current findings and necessary steps for future research.